Table 2: The data regarding the rate of diagnosed diseases included in the new ASFA guideline[1] and of the utility of therapeutic apheresis procedures in our center.

Diseases	Diagnosis No	TA (type/No)
Atopic (neuro-) dermatitis, recalcitrant	71	-
Complex regional pain syndrome	0	-
Erythropoietic porphyria, liver disease	0	-
Hashimoto's encephalopathy	1 (not definite, but as rule out)	-
HELLP syndrome	1	TPE/3
Hemophagocytic lymphohistiocytosis	9	-
N-methyl D-aspartate receptor antibody encephalitis	0	-
Prevention of RhD alloimmunization after RBC exposure	0	-
Progressive multifocal leukoencephalopathy associated with natalizumab	0	-
Pruritus due to hepatobiliary disease	6	-
Thrombotic microangiopathy-coagulation mediated	0	-
Vasculitis (Behçet's disease)	29	0
Total	**117**	**3**

No: number, TA: therapeutic apheresis, HELLP: hemolysis, elevated liver enzymes, and a low platelet count, RBC: red blood cell, TPE: therapeutic plasma exchange.